Literature DB >> 11078767

Relapses and progression of disability in multiple sclerosis.

C Confavreux1, S Vukusic, T Moreau, P Adeleine.   

Abstract

BACKGROUND: The influence of the patterns of onset of multiple sclerosis and relapses of the disease on the time course of irreversible disability is controversial.
METHODS: In 1844 patients with multiple sclerosis who were followed for a mean (+/- SD) of 11 +/- 10 years, we determined the time of the clinical onset of the disease, the initial course (relapsing-remitting or progressive) and the subsequent course (relapsing-remitting, secondary progressive, or primary progressive), the times of relapses, the time to the onset of irreversible disability, and the time course of progressive, irreversible disability. We used three scores on the Kurtzke Disability Status Scale (range, 0 to 10, with higher scores indicating more severe disability) as measures of the severity and progression of disability: a score of 4 (limited walking ability but able to walk for more than 500 m without aid or rest), a score of 6 (ability to walk with unilateral support no more than 100 m without rest), and a score of 7 (ability to walk no more than 10 m without rest while leaning against a wall or holding onto furniture for support). We used Kaplan-Meier analyses to determine the influence of relapses on the time to the onset of irreversible disability.
RESULTS: The median times from the onset of multiple sclerosis to the assignment of a score of 4, a score of 6, and a score of 7 on the disability scale were longer among the 1562 patients with a relapsing-remitting onset of disease (11.4, 23.1, and 33.1 years, respectively) than among the 282 patients who had progressive disease from the onset (0.0, 7.1, and 13.4 years, respectively; P<0.001 for all comparisons). In contrast, the times from the assignment of a score of 4 to a score of 6 were similar in the two groups (5.7 and 5.4 years, P=0.74). The time course of progressive, irreversible disease among patients with the primary progressive type of multiple sclerosis was not affected by the presence or absence of superimposed relapses.
CONCLUSIONS: Among patients with multiple sclerosis, relapses do not significantly influence the progression of irreversible disability.

Entities:  

Mesh:

Year:  2000        PMID: 11078767     DOI: 10.1056/NEJM200011163432001

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  247 in total

1.  Natural history of multiple sclerosis.

Authors:  G C Ebers
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

Review 2.  Interferon in relapsing-remitting multiple sclerosis.

Authors:  G P Rice; B Incorvaia; L Munari; G Ebers; C Polman; R D'Amico; G Filippini
Journal:  Cochrane Database Syst Rev       Date:  2001

Review 3.  Immunologic therapy for relapsing-remitting multiple sclerosis.

Authors:  H J MacLean; M S Freedman
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

4.  [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].

Authors:  M E Kornhuber; S Zierz
Journal:  Nervenarzt       Date:  2003-05-14       Impact factor: 1.214

5.  Relapses and disability accumulation in progressive multiple sclerosis.

Authors:  M Mateo Paz Soldán; Martina Novotna; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2014-11-14       Impact factor: 9.910

6.  The course of early-onset multiple sclerosis in Iraqi children.

Authors:  Hasan A Al-Hamadani; Atheer S Abdalla; Atheer J Al-Saffar
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

7.  MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability.

Authors:  D S Meier; H L Weiner; C R G Guttmann
Journal:  AJNR Am J Neuroradiol       Date:  2007 Nov-Dec       Impact factor: 3.825

8.  Role of pathogenic T cells and autoantibodies in relapse and progression of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in LEW.1AV1 rats.

Authors:  Yoh Matsumoto; Il-Kwon Park; Keiko Hiraki; Shin Ohtani; Kuniko Kohyama
Journal:  Immunology       Date:  2008-10-29       Impact factor: 7.397

Review 9.  Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.

Authors:  Regina Berkovich; Mark A Agius
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

10.  Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.

Authors:  Richard K Burt; Roumen Balabanov; Joachim Burman; Basil Sharrack; John A Snowden; Maria Carolina Oliveira; Jan Fagius; John Rose; Flavia Nelson; Amilton Antunes Barreira; Kristina Carlson; Xiaoqiang Han; Daniela Moraes; Amy Morgan; Kathleen Quigley; Kimberly Yaung; Regan Buckley; Carri Alldredge; Allison Clendenan; Michelle A Calvario; Jacquelyn Henry; Borko Jovanovic; Irene B Helenowski
Journal:  JAMA       Date:  2019-01-15       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.